ES2191977T3 - Soluciones y dispersiones en estado solido de farmacos poco solubles en agua. - Google Patents

Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.

Info

Publication number
ES2191977T3
ES2191977T3 ES98955458T ES98955458T ES2191977T3 ES 2191977 T3 ES2191977 T3 ES 2191977T3 ES 98955458 T ES98955458 T ES 98955458T ES 98955458 T ES98955458 T ES 98955458T ES 2191977 T3 ES2191977 T3 ES 2191977T3
Authority
ES
Spain
Prior art keywords
water
pharmacos
solubles
dispersions
little
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98955458T
Other languages
English (en)
Inventor
Siva Narayan Tallavajhala
Xiuying Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2191977T3 publication Critical patent/ES2191977T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La invención describe una composición útil como excipiente farmacéutico, el procedimiento de producción del mismo y las composiciones farmacéuticas producidas de esta manera. En particular, la invención se aplica para mejorar la solubilidad de los compuestos terapéuticamente activos ligeramente solubles en agua, por medio de un excipiente que comprende una mezcla de : (a) glicéridos poliglicolizados saturados y (b) copolímeros secuenciados polioxipropileno - polioxietileno, en la que se mejora la solubilidad del compuesto terapéuticamente activo poco soluble en la composición farmacéutica.
ES98955458T 1997-10-27 1998-10-15 Soluciones y dispersiones en estado solido de farmacos poco solubles en agua. Expired - Lifetime ES2191977T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6333897P 1997-10-27 1997-10-27

Publications (1)

Publication Number Publication Date
ES2191977T3 true ES2191977T3 (es) 2003-09-16

Family

ID=22048528

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98955458T Expired - Lifetime ES2191977T3 (es) 1997-10-27 1998-10-15 Soluciones y dispersiones en estado solido de farmacos poco solubles en agua.

Country Status (10)

Country Link
EP (1) EP0996429B1 (es)
JP (1) JP2001520984A (es)
CN (1) CN1190187C (es)
AT (1) ATE232087T1 (es)
DE (1) DE69811233T2 (es)
DK (1) DK0996429T3 (es)
ES (1) ES2191977T3 (es)
NO (1) NO329755B1 (es)
PT (1) PT996429E (es)
WO (1) WO1999021534A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775597B1 (fr) * 1998-03-04 2001-04-20 Gattefosse Ets Sa Pellet administrable par voie orale apte a ameliorer la biodisponibilite de la substance active, procede de fabrication
WO1999063841A1 (en) * 1998-06-05 1999-12-16 Forbes Medi-Tech Inc. Compositions comprising phytosterol and/or phytostanol having enhanced solubility and dispersability
US20030166525A1 (en) 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
SE9901667D0 (sv) * 1999-05-07 1999-05-07 Astra Ab Method and device for forming particles
SE9902742D0 (sv) * 1999-07-20 1999-07-20 Astra Ab New pharmaceutical formultion
US20010036479A1 (en) * 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
ITMI20011338A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio immediato del principio attivo
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
CN101961317A (zh) * 2001-07-06 2011-02-02 生命周期药物公司 受控制的凝聚
IS6633A (is) * 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
BR0215979A (pt) * 2002-12-13 2005-11-01 Jagotec Ag Formulação de espironolactona nanoparticulada tópica, uso de nanossuspensões de espironolactona, sistema de rede cristalina, e, processo para a preparação de uma formulação de espironolactona nanoparticulada tópica
CA2514875A1 (en) * 2003-02-19 2004-09-02 Biovail Laboratories International Srl Rapid absorption selective 5-ht agonist formulations
AU2004226666B9 (en) 2003-04-02 2010-04-08 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
AU2004248931B2 (en) 2003-06-20 2009-07-16 Ares Trading S.A. Freeze-dried FSH / LH formulations
CN1901885A (zh) * 2003-11-13 2007-01-24 阿尔扎公司 包含低水溶性药物和环氧乙烷－环氧丙烷嵌段共聚物的熔混分散体
US8974823B2 (en) 2003-12-31 2015-03-10 Bend Research, Inc. Solid compositions of low-solubility drugs and poloxamers
TW200616681A (en) * 2004-10-05 2006-06-01 Recordati Ireland Ltd Lercanidipine capsules
ATE411817T1 (de) * 2004-11-17 2008-11-15 Ares Trading Sa Benzothiazolformulierungen und ihre verwendung
EP1690528A1 (de) * 2005-02-11 2006-08-16 Abbott GmbH & Co. KG Herstellung von Dosierungsformen mit einer festen Dispersion eines mikrokristallinen Wirkstoffs
ES2277767B1 (es) * 2005-11-04 2008-04-01 Simbec Iberica, S.L. Formas orales solidas de ebastina.
ATE482690T1 (de) * 2005-12-14 2010-10-15 Hoffmann La Roche Hcv-prodrug-formulierung
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP1972336A1 (en) * 2007-03-19 2008-09-24 LEK Pharmaceuticals D.D. Hot-melt micropellets
WO2010143199A1 (en) * 2009-06-11 2010-12-16 Suven Nishtaa Pharma Private Limited Solid lipid dispersion for aqueous solubility enhancement of poorly water soluble drugs
US20120322752A1 (en) * 2009-12-08 2012-12-20 Sung Kyun Lee SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US8895536B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating chronic inflammation and inflammatory diseases
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
UA114469C2 (uk) 2010-11-01 2017-06-26 Мелінта Терап'Ютікс, Інк. Фармацевтична композиція, що містить протимікробний агент
EP2455068A1 (en) * 2010-11-09 2012-05-23 F. Hoffmann-La Roche AG Pharmaceutical composition for treating HCV infections
CN111700880A (zh) * 2012-05-03 2020-09-25 卡拉制药公司 显示提高的粘膜转移的药物纳米粒子
DE102012105512A1 (de) * 2012-06-25 2014-04-24 Hennig Arzneimittel Gmbh & Co. Kg Arzneiform zur verlängerten Freisetzung von Wirkstoffen
US10994013B2 (en) 2013-04-24 2021-05-04 Temple University—Of the Commonwealth System of Higher Education Solid dosage form containing arabinogalactan
US20160151503A1 (en) * 2013-08-01 2016-06-02 Mw Encap Limited Compositions and preparation methods of low melting ionic salts of poorly-water soluble drugs
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
US12343430B2 (en) 2019-04-08 2025-07-01 Mudanjiang Linrun Pharama Excipients Llc. Methods of improving pharmaceutical substance solubilization and products thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8524421D0 (en) * 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
JPH05255125A (ja) * 1992-02-29 1993-10-05 Upjohn Co:The 徐放性製剤およびその製法
JPH06316517A (ja) * 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
US5487887A (en) * 1993-10-28 1996-01-30 Bristol-Myers Squibb Company Clear antiperspirant roll-on compositions
US5545628A (en) * 1995-01-10 1996-08-13 Galephar P.R. Inc. Pharmaceutical composition containing fenofibrate
JPH08268878A (ja) * 1995-03-06 1996-10-15 Yoshiyuki Masui 経口医薬品並びに加工食品
US5883103A (en) * 1995-06-07 1999-03-16 Shire Laboratories Inc. Oral acyclovir delivery
FR2761265B1 (fr) * 1997-03-28 1999-07-02 Sanofi Sa Composition pharmaceutique pour l'administration orale d'un derive du n-piperidino-3-pyrazolecarboxamide, de ses sels et de leurs solvates

Also Published As

Publication number Publication date
WO1999021534A1 (en) 1999-05-06
DE69811233T2 (de) 2003-11-20
NO329755B1 (no) 2010-12-13
DE69811233D1 (de) 2003-03-13
PT996429E (pt) 2003-06-30
CN1278164A (zh) 2000-12-27
DK0996429T3 (da) 2003-05-26
NO20002133D0 (no) 2000-04-26
NO20002133L (no) 2000-04-26
EP0996429B1 (en) 2003-02-05
JP2001520984A (ja) 2001-11-06
EP0996429A1 (en) 2000-05-03
ATE232087T1 (de) 2003-02-15
CN1190187C (zh) 2005-02-23

Similar Documents

Publication Publication Date Title
UY26977A1 (es) Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgésicos
JOP20210301A1 (ar) بيرولات ثلاثية الحلقة مكثفة كمُعدِّلات مضاد تريبسين ألفا-1
DE60142891D1 (de) Azetidinderivate enthaltende pharmazeutische zusammensetzungen, die azetidinderivate und deren herstellung
AR028833A1 (es) Compuestos inhibidores de metaloproteasas, composiciones farmaceuticas, uso para la manufactura de medicamentos, metodo de tratamiento y procedimiento para su preparacion
AR030609A1 (es) Composicion catartica
CO5680109A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
PA8591701A1 (es) Derivados de pirrolopirimidina
PE20030823A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
BR0114799A (pt) Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos
UY27368A1 (es) Nuevos compuestos
DK0996429T3 (da) Faste opløsninger og faste dispersioner i vand tungtopløselige lægemidler
ECSP034826A (es) Método para fabricar una composición farmacéutica de dosis baja
BR0207872A (pt) Composto para liberar agentes ativos, composição, forma de unidade de dosagem e método de administração
ES2188604T3 (es) Inhibidores de proteasa del vih en combinaciones farmaceuticas para eltratamiento del sida.
ECSP055528A (es) Composicion farmaceutica que tiene una distribución y potencia uniforme de farmaco
ES2188426B1 (es) Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias.
DK1638582T3 (da) Anvendelse af hyaluronsyre til fremstilling af kompositioner til behandling af tilbagevendende after
DK1109560T3 (da) Som AICARFT-inhibitorer anvendelige forbindelser
AR001769A1 (es) Benzamida enterocinética composiciones farmacéuticas que las contienen procedimiento para la preparación de dichas composiciones farmacéuticas el uso de dichos compuestos para la manufactura de medicamentos y un procedimiento para su preparación
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
AR035064A1 (es) 3-(1-metil-3-indolil)-4-(1-metil-6-nitro-3-indolil)-1h-pirrol-2,5-diona, en forma amorfa, procesos para prepararla, composicion farmaceutica que la comprende y uso de dicho compuesto en la fabricacion de medicamentos
AR026451A1 (es) Compuestos heterociclicos sililados
NO20022000L (no) 6-metoksy-2-naftyleddiksyre-prodrogesammensetninger til behandling av inflammasjon
AR021491A1 (es) Un compuesto de 6-azauracilo que inhibe a il-5, una composicion que lo comprende, un proceso para preparar dicha composicion, y el uso de dicho compuestopara la manufactura de un medicamento y de un agente de diagnostico
AR005730A1 (es) Forma de fanciclovir, procedimiento para prepararla, composiciones farmaceuticas que la contienen y metodo para el tratamiento o profilaxis deinfecciones virales y el uso de dicha forma -fanciclovir monoidrato.